SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (51541)2/10/2000 1:02:00 AM
From: Oral Roberts  Respond to of 122087
 
A
I am a long time lurker and just had to say a couple of things. I don't know why you bother to try and help anyone (I guess that I have become a cynic) because whenever you do you just expose yourself to the butts of the world. I also don't know why you just don't go quietly about your business and make money cause then you would not have to deal with the butts of the world, but I must thank you because I have learned much by watching you over the years thanks.

Jeff Roberts

PS Be aware that I guarded my Scottish and WI temper and kept the profanity that I would liked to have used out my post:)



To: Anthony@Pacific who wrote (51541)2/10/2000 1:54:00 AM
From: SkyDart  Read Replies (2) | Respond to of 122087
 
WHY SNRS WAS A GOOD SHORT:

Hey Anthony,

I agree with you that SNRS was a great short.

SNRS Float 44 million shares
SNRS Revenue = 20 thousand per year.

Price to Revenue = 3,000

Why Shorting BBII is suicide:

BBII Float 2.6 million
BBII Revenue = 20 million per year

Price to Revenue = .85

And revenues from HIV antigen testing estmated 30 to 50 more million per year.

Good Luck,

Dart


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News